Exciting Breakthrough: Moderna’s Flu Vaccine Shines in Late-Stage Trials, Setting the Stage for a Combined COVID Vaccine

Moderna recently revealed that its new mRNA-based flu vaccine is showing promise. In late-stage trials, it triggered a stronger immune response compared to the currently available vaccine. This development also paves the way for Moderna’s combination vaccine that targets both flu and COVID-19.

Earlier this year, Moderna voluntarily pulled back its application for the combined vaccine to gather more data, especially after discussions with the FDA. This came during a significant shift in FDA policies under new leadership.

With recent encouraging data, Moderna plans to resubmit its application by the end of the year for both the standalone flu shot and the combination vaccine. If all goes well, the company expects to receive regulatory approval next year.

Stephen Hoge, Moderna’s head of research and development, mentioned that these vaccines could simplify the vaccination process. Fewer shots for patients could ease the burden on healthcare providers and boost vaccination rates.

Notably, in a trial involving over 40,000 adults aged 50 and older, Moderna’s vaccine was found to be 26.6% more effective than the traditional flu shot. It also proved beneficial across various flu strains and demographics. For adults over 65, it was even 27.4% more effective, highlighting its importance, especially given the high hospitalization rates seen in the last flu season. According to the CDC, over 600,000 people were hospitalized in the past year due to flu.

The push for more effective vaccines has never been more critical. The CDC reported that flu-related hospitalizations hit a 15-year high recently. The severe flu season underscores the demand for better options, especially for vulnerable groups.

Despite a challenging year, where Moderna’s shares dropped significantly due to political changes affecting vaccine policies, there’s cautious optimism. Hoge stated that they are closely collaborating with FDA to meet the new requirements.

As the vaccine landscape evolves, it’s clear that efficient and potent vaccines are vital for public health. A combination flu and COVID-19 vaccine could be a game-changer, making it easier for everyone to stay protected.

For further information, you can check the CDC’s flu data here.

Source link

Breaking News: Business,Health care industry,Pharmaceuticals,Biotech and Pharmaceuticals,Biotechnology,Business,Moderna Inc,Stéphane Bancel,Pfizer Inc,Novavax Inc,Robert F. Kennedy Jr.,business news